Black Diamond Therapeutics (NASDAQ:BDTX) Given Buy Rating at HC Wainwright

HC Wainwright reissued their buy rating on shares of Black Diamond Therapeutics (NASDAQ:BDTX) in a research note issued to investors on Wednesday morning, Benzinga reports. HC Wainwright currently has a $11.00 price target on the stock.

Several other research firms have also issued reports on BDTX. Piper Sandler reaffirmed an overweight rating and issued a $12.00 target price on shares of Black Diamond Therapeutics in a report on Wednesday, July 3rd. Raymond James assumed coverage on Black Diamond Therapeutics in a research report on Wednesday, July 31st. They set an outperform rating and a $20.00 target price for the company. Finally, Wedbush reissued an outperform rating and issued a $16.00 price target on shares of Black Diamond Therapeutics in a report on Tuesday, September 10th.

Black Diamond Therapeutics Trading Down 2.0 %

Shares of NASDAQ:BDTX opened at $4.73 on Wednesday. The stock has a market cap of $266.08 million, a PE ratio of -2.85 and a beta of 2.49. The stock’s fifty day simple moving average is $5.72 and its two-hundred day simple moving average is $5.35. Black Diamond Therapeutics has a 1-year low of $1.62 and a 1-year high of $7.66.

Black Diamond Therapeutics (NASDAQ:BDTX) last released its quarterly earnings results on Tuesday, August 6th. The company reported ($0.36) earnings per share for the quarter, topping the consensus estimate of ($0.39) by $0.03. On average, sell-side analysts forecast that Black Diamond Therapeutics will post -1.4 earnings per share for the current fiscal year.

Institutional Trading of Black Diamond Therapeutics

A number of large investors have recently bought and sold shares of the company. Susquehanna Fundamental Investments LLC bought a new position in shares of Black Diamond Therapeutics during the 1st quarter worth $82,000. SG Americas Securities LLC bought a new position in Black Diamond Therapeutics during the second quarter worth about $108,000. Jump Financial LLC increased its stake in shares of Black Diamond Therapeutics by 245.0% in the fourth quarter. Jump Financial LLC now owns 38,888 shares of the company’s stock worth $109,000 after purchasing an additional 27,616 shares in the last quarter. Algert Global LLC bought a new stake in shares of Black Diamond Therapeutics in the second quarter valued at approximately $133,000. Finally, Pale Fire Capital SE purchased a new stake in shares of Black Diamond Therapeutics during the 4th quarter valued at approximately $144,000. 95.47% of the stock is owned by hedge funds and other institutional investors.

About Black Diamond Therapeutics

Black Diamond Therapeutics, Inc, a clinical-stage oncology medicine company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as phase 1 clinical trial to treat glioblastoma.